We have written about a handful of diabetes related stocks in the past and one of them is showing some great upside potential. With the momentum this stock has shown and the potential for growth in their space Tandem (TNDM) is lagging a bit behind the rest of the pack. Here is a chart of the last two years:
Even from the last time we mentioned it about a month ago, it has jumped 10%. Tandem recently announced some new developments on the horizon that will broaden its market and open up room for growth.
While I think it will hold up well in the short term, this is definitely on my long term hold list and I am expecting it to out perform in 2022.
If you are looking for ways to line up your trading plans for next year, scroll down and take advantage of the collection of free books that have some great tips and refreshers that can open your eyes to some productive ideas for your 2022 plans.
Keep learning and trade wisely,
Market Wealth Daily